Sigilon Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company developing functional cures for patients with chronic diseases, completed an $80.3m Series B financing.
Canada Pension Plan Investment Board (CPP Investments), Longevity Vision Fund and funds managed by BlackRock joined founding investor Flagship Pioneering and other existing investors, including Eli Lilly and Company, in the financing round, which brings Sigilon’s total funding to more than $195m.
The company intends to use the funds for first-in-human clinical trial of its novel encapsulated cell therapy for hemophilia A, expected to begin in the first half of 2020, as well as continued advancement and expansion of programs in rare blood disorders, lysosomal diseases and endocrine and immune disorders.
Founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology and led by Rogerio Vivaldi, M.D., President and CEO, Sigilon was founded to develop immune-protected, bio-engineered cells to restore normal physiology in a wide range of diseases without immune rejection, liberating patients from the challenges associated with existing treatments for serious chronic diseases. Treatments based on its Shielded Living Therapeutics platform combine advanced cell engineering with innovations in biocompatible materials to pioneer a new class of medicines that have been designed to provide durable, redosable, controllable and safe potential treatment for chronic diseases. Sigilon’s lead investigational therapy for hemophilia A, SIG-001, has received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). Sigilon expects to initiate a clinical trial of SIG-001 in the first half of 2020.